Kim, Jeong Eun; Ryoo, Baek-Yeol; Ryu, Min-Hee; Chang, Heung-Moon; Suh, Dong Jin; Lee, Han Chu; Lim, Young-Suk; Kim, Kang Mo; Kang, Yoon-Koo
Cancer chemotherapy and pharmacology
2011Nov ; 68 ( 5 ) :1285-90.
PMID : 21445543
ÀúÀÚ »ó¼¼Á¤º¸
Kim, Jeong Eun -
Ryoo, Baek-Yeol -
Ryu, Min-Hee -
Chang, Heung-Moon -
Suh, Dong Jin -
Lee, Han Chu -
Lim, Young-Suk -
Kim, Kang Mo -
Kang, Yoon-Koo -
ABSTRACT
PURPOSE: We compared the efficacy and safety of sorafenib in patients with Child-Pugh (CP) class B and CP class A.
METHODS: Clinical data from 267 patients with HCC who had been treated with sorafenib were reviewed. Patients were grouped according to CP score (5-6, 7, and 8-9), and their tumor response, tolerance, and survival were assessed.
RESULTS: Median patient age was 55?years, and 87.6% were men. Gender, HCC etiology, and extrahepatic metastasis did not differ according to CP score. Of the 225 evaluable patients, 4 achieved partial response and 121 achieved stable disease, making the disease control rate 46.8%. DCR was higher in patients with CP A than CP B score, but did not differ between those with CP scores of 7 and 8-9. The incidence rates of grade 3/4 toxicities did not differ according to CP score. Many patients with CP score 8-9 (26.3%) had to stop sorafenib due to cirrhosis-related complications. At a median follow-up of 15.6?months, the median time to progression and overall survival of all patients were 2.6 and 7.9?months, respectively. OS was greater in patients with CP score 5-6 than in patients with CP scores of 7 or 8-9.
CONCLUSIONS: Sorafenib efficacy and survival outcomes were worse in patients with CP B function. Patients with a CP score of 7 had the same incidence of adverse events and cirrhosis-related complications as those with CP A liver function, suggesting that the former can be included in clinical trials of new agents.
Hepatocellular carcinoma, Sorafenib, Child-Pugh class. sorafenib efficacy and survival outcomes were worse in patients with CP B than CP A liver function and that the incidence of cirrhosis-related complications interrupting sorafenib treatment was higher in patients with CP scores ¡Ã 8
MESH
Adult, Aged, Aged, 80 and over, Antineoplastic Agents/adverse effects/*therapeutic use, Benzenesulfonates/adverse effects/*therapeutic use, Carcinoma, Hepatocellular/*drug therapy, Female, Humans, Liver Neoplasms/*drug therapy, Male, Middle Aged, Niacinamide/analogs & derivatives, Phenylurea Compounds, Pyridines/adverse effects/*therapeutic use, Treatment Outcome
¸µÅ©